主页 > 医学前沿 >
【medical-news】感染性心内膜炎慎用阿司匹林：未
NEW YORK (Reuters Health) Jan 11 - In patients with infective endocarditis, long-term daily use of aspirin does not reduce the risk of embolic events and may increase the risk of bleeding, report clinicians from Canada in the January 1 issue of Clinical Infectious Diseases.
The findings stem from a post-hoc analysis of 139 patients from the Multi-Centre Aspirin Trial in Infective Endocarditis, a randomized trial assessing the effect of aspirin on embolic events in the acute phase of infective endocarditis.
Included in the analysis were 84 patients randomized to aspirin -- most commonly 325 mg/day -- before and during the early stages of infective endocarditis and 55 patients allocated to placebo.
According to Dr. Kwan-Leung Chan of the University of Ottawa Heart Institute, Ontario, and colleagues, there was a trend toward excess bleeding (major or minor) during hospitalization in patients taking aspirin compared to those not taking aspirin (p = 0.065).
This association was supported by logistic models, although the association did not quite reach statistical significance, the investigators note. In the adjusted model, the odds ratio for bleeding was 2.08 for long-term aspirin recipients.
Moreover, use of aspirin did not alter the risk of embolism in either the unadjusted or adjusted model.
Based on these data, the investigators say aspirin "should be used with caution in the acute treatment of infective endocarditis."
They further recommend that, for patients who are already taking aspirin and who receive a diagnosis of endocarditis, "the need for aspirin should be carefully assessed, and the risk-benefit of discontinuation of aspirin should be considered to minimize the risk of bleeding during the acute phase of endocarditis."
Clin Infect Dis 2008;46:37-41.
http://www.medscape.com/viewarticle/568689 Aspirin No Benefit in Infective Endocarditis
在感染性心内膜炎中使用阿司匹林没有益处
NEW YORK (Reuters Health) Jan 11 - In patients with infective endocarditis, long-term daily use of aspirin does not reduce the risk of embolic events and may increase the risk of bleeding, report clinicians from Canada in the January 1 issue of Clinical Infectious Diseases.
纽约（路透社健康新闻）1月11日――来自加拿大的临床医生们在1月刊的《临床感染疾病》杂志发表报道：在感染性心内膜炎的患者中，长期服用阿司匹林不能降低血栓的危险，反而可能增加出血的危险。
The findings stem from a post-hoc analysis of 139 patients from the Multi-Centre Aspirin Trial in Infective Endocarditis, a randomized trial assessing the effect of aspirin on embolic events in the acute phase of infective endocarditis.
研究的发现结果来源于139位参与多中心阿司匹林临床研究的，患有感染性心内膜炎的患者的数据专职分析，多中心阿司匹林试验是一个评价在急性期的感染性心内膜炎的患者中使用阿司匹林对血栓是否有影响的随机试验。
Included in the analysis were 84 patients randomized to aspirin -- most commonly 325 mg/day -- before and during the early stages of infective endocarditis and 55 patients allocated to placebo.
分析数据包括84位在感染性心内膜炎急性期前和正在急性期的使用阿司匹林的感染性心内膜炎患者（大多数的剂量是325 mg/天），以及服用安慰剂的55位患者，服用安慰剂或阿司匹林是随机的。
According to Dr. Kwan-Leung Chan of the University of Ottawa Heart Institute, Ontario, and colleagues, there was a trend toward excess bleeding (major or minor) during hospitalization in patients taking aspirin compared to those not taking aspirin (p = 0.065).
根据Kwan-Leung Chan博士和他同事们的研究结果，使用阿司匹林与没有使用阿司匹林的患者相比在住院期间似乎有出血（大出血或小出血）的趋势(p = 0.065)。Kwan-Leung Chan博士目前就职于安大略省的渥太华心脏研究中心。
This association was supported by logistic models, although the association did not quite reach statistical significance, the investigators note. In the adjusted model, the odds ratio forbleeding was 2.08 for long-term aspirin recipients.
研究者们注说，logistic模型研究的也支持这样的关联，虽然此种关联没有达到统计学的显著差异。在效准后的模型中，长期服用阿司匹林患者的.出血优势比为2.08。
Moreover, use of aspirin did not alter the risk of embolism in either the unadjusted or adjusted model
在效准和未效准模型均发现，阿司匹林并末改变血栓的危险性。
Based on these data, the investigators say aspirin "should be used with caution in the acute treatment of infective endocarditis."
根据这些数据，研究者们声称阿司匹林“在感染性心内膜炎的急性期的使用应该谨慎。”
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-05-23 17:14
医学,生命科学网